Abstract
Bellini Duct Carcinoma is a rare and aggressive type of Renal Cancer which shares histological and clinical features with Transitional cell carcinomas. We present the two single cases recorded in our hospital with a medical literature review. Although there are no exact guidelines to treat this disease, when is disseminated we normally used chemotherapy schemes based on platinum salt like in Urothelial cancer. The targeted therapy should be considered for the treatment of metastatic collecting duct carcinoma but a prospective evaluation is necessary in multicenter clinical trials.
Highlights
Bellini Duct Carcinoma is known as a rare variant of renal cancer originating from the Collecting tubules, unlike all other renal tumors which originate from the proximal tubules
Chemotherapy schemes similar to those used for Urothelial tumors being employed, we present two cases of this disease arising at our Hospital for reviewing the currently-existing literature concerning this disease
The efficacy of the target treatments in renal Cancer has not been evaluated in these tumors in clinical trials, isolated cases with modest response to both Tyrosine kinase inhibitors and m-TOR kinase inhibitors have been reported [8,13,14].Targeted therapy should be considered for the treatment of metastatic collecting duct carcinoma and its prospective evaluation is encouraged
Summary
Bellini Duct Carcinoma is known as a rare variant of renal cancer originating from the Collecting tubules, unlike all other renal tumors which originate from the proximal tubules. Fleming and Lewi [3] defined the diagnostic criterion and established it as a different diagnostic entity originating from the renal medulla These sorts of tumors present an early dissemination and fatal clinical course in addition to histological characteristics similar to Urothelial tumoral types. A renal mass, being diagnosed with Bellini Duct Carcinoma Two years later, he presents lung, bone and lymph node metastasis and a lung FNAB (fine-needle biopsy aspiratory) being performed, confirming the recurrence. The patient received a new chemotherapy scheme with Docetaxel 75 mg/m2, undergoing exclusively one cycle Thereafter he showed a suddenly deterioration of his overall condition and death occurred three months following the relapse due to respiratory complications and two years after the diagnostic of renal cancer. The patient’s condition worsened at 7 months of the diagnosis starting Palliative Care control with an optimal symptom management but he died a month later
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
